Take Solutions Limited - Asset Resilience Ratio
Take Solutions Limited (TAKE) has an Asset Resilience Ratio of 41.29% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read TAKE total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how Take Solutions Limited's Asset Resilience Ratio has changed over time. See Take Solutions Limited (TAKE) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Take Solutions Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Take Solutions Limited market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs1.50 Million | 0.43% |
| Short-term Investments | Rs143.90 Million | 40.87% |
| Total Liquid Assets | Rs145.40 Million | 41.29% |
Asset Resilience Insights
- Very High Liquidity: Take Solutions Limited maintains exceptional liquid asset reserves at 41.29% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Take Solutions Limited Industry Peers by Asset Resilience Ratio
Compare Take Solutions Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Take Solutions Limited (2002–2025)
The table below shows the annual Asset Resilience Ratio data for Take Solutions Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 8.10% | Rs29.54 Million ≈ $319.46K |
Rs364.79 Million ≈ $3.95 Million |
+8.09pp |
| 2024-03-31 | 0.00% | Rs40.00K ≈ $432.58 |
Rs881.05 Million ≈ $9.53 Million |
-4.79pp |
| 2023-03-31 | 4.80% | Rs107.60 Million ≈ $1.16 Million |
Rs2.24 Billion ≈ $24.27 Million |
+2.42pp |
| 2022-03-31 | 2.38% | Rs290.71 Million ≈ $3.14 Million |
Rs12.23 Billion ≈ $132.27 Million |
+2.36pp |
| 2021-03-31 | 0.02% | Rs2.77 Million ≈ $29.96K |
Rs18.45 Billion ≈ $199.49 Million |
-0.23pp |
| 2020-03-31 | 0.25% | Rs60.99 Million ≈ $659.58K |
Rs24.83 Billion ≈ $268.55 Million |
-9.50pp |
| 2019-03-31 | 9.75% | Rs2.28 Billion ≈ $24.60 Million |
Rs23.34 Billion ≈ $252.40 Million |
-5.18pp |
| 2018-03-31 | 14.93% | Rs2.75 Billion ≈ $29.76 Million |
Rs18.44 Billion ≈ $199.38 Million |
+14.51pp |
| 2017-03-31 | 0.41% | Rs56.92 Million ≈ $615.57K |
Rs13.73 Billion ≈ $148.45 Million |
+0.28pp |
| 2016-03-31 | 0.14% | Rs16.70 Million ≈ $180.60K |
Rs12.14 Billion ≈ $131.34 Million |
-0.01pp |
| 2015-03-31 | 0.15% | Rs13.50 Million ≈ $146.00K |
Rs9.22 Billion ≈ $99.75 Million |
-5.67pp |
| 2014-03-31 | 5.81% | Rs501.50 Million ≈ $5.42 Million |
Rs8.62 Billion ≈ $93.27 Million |
-0.18pp |
| 2013-03-31 | 5.99% | Rs501.60 Million ≈ $5.42 Million |
Rs8.37 Billion ≈ $90.50 Million |
-0.78pp |
| 2012-03-31 | 6.77% | Rs501.60 Million ≈ $5.42 Million |
Rs7.41 Billion ≈ $80.10 Million |
-1.74pp |
| 2011-03-31 | 8.51% | Rs500.00 Million ≈ $5.41 Million |
Rs5.88 Billion ≈ $63.54 Million |
-3.68pp |
| 2010-03-31 | 12.19% | Rs626.01 Million ≈ $6.77 Million |
Rs5.13 Billion ≈ $55.52 Million |
+1.28pp |
| 2009-03-31 | 10.92% | Rs562.23 Million ≈ $6.08 Million |
Rs5.15 Billion ≈ $55.70 Million |
+1.67pp |
| 2008-03-31 | 9.25% | Rs367.88 Million ≈ $3.98 Million |
Rs3.98 Billion ≈ $43.03 Million |
+5.93pp |
| 2007-03-31 | 3.31% | Rs85.61 Million ≈ $925.82K |
Rs2.58 Billion ≈ $27.95 Million |
+1.20pp |
| 2006-03-31 | 2.11% | Rs19.08 Million ≈ $206.34K |
Rs905.33 Million ≈ $9.79 Million |
-4.13pp |
| 2005-03-31 | 6.24% | Rs12.16 Million ≈ $131.51K |
Rs194.89 Million ≈ $2.11 Million |
+3.44pp |
| 2004-03-31 | 2.80% | Rs3.96 Million ≈ $42.83K |
Rs141.45 Million ≈ $1.53 Million |
+2.06pp |
| 2003-03-31 | 0.74% | Rs700.00K ≈ $7.57K |
Rs94.72 Million ≈ $1.02 Million |
-0.77pp |
| 2002-03-31 | 1.51% | Rs450.00K ≈ $4.87K |
Rs29.90 Million ≈ $323.36K |
-- |
About Take Solutions Limited
TAKE Solutions Limited, together with its subsidiaries, provides domain-intensive services in life sciences and software and information technology in India. The company offers clinical research, generics development, data sciences, regulatory affairs, and pharmacovigilance and safety services backed by technology expertise. It also provides embed digital and employ mobile solutions for patient c… Read more